文献速递银屑病与炎症性皮肤病

Tapinarof乳膏治疗斑块状银屑病的2b期随机临床试验:次要疗效与患者报告结局

A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
PubMed 文献 · J Am Acad Dermatol · 2020-05-21

这项2b期双盲、赋形剂对照研究纳入斑块状银屑病成人患者,随机接受Tapinarof乳膏0.5%或1%每日一次或两次、或赋形剂治疗12周并随访4周。第12周时,所有Tapinarof组在PGA应答、PGA及靶皮损总评分变化、PASI50(71%-92% vs 10%-32%)、PASI75(46%-65% vs 5%-16%)和PASI90(18%-40% vs 0%)方面均优于赋形剂,其中1%每日一次组所有差异均具统计学显著性。Tapinarof应答自第2周显现,第8周显著疗效维持至第16周。

要点

  • Tapinarof乳膏0.5%/1%每日一次或两次治疗斑块状银屑病12周,PASI50达71%-92%,赋形剂组10%-32%。
  • PASI75为46%-65% vs 5%-16%,PASI90为18%-40% vs 0%,1%每日一次组差异均显著。
  • 疗效自第2周显现,第8周显著并维持至第16周;多数不良事件为轻中度。

核心结论

  • Tapinarof乳膏可能代表银屑病外用药物研发的重要进展。

研究设计与样本

  • 2b期、双盲、赋形剂对照研究,纳入斑块状银屑病成人患者,随机接受Tapinarof乳膏0.5%或1%每日一次或两次、或赋形剂每日一次或两次治疗12周,随访4周。

主要发现

  • 第12周时,所有Tapinarof组在PGA应答、PGA及靶皮损总评分变化、PASI50(71%-92% vs 10%-32%)、PASI75(46%-65% vs 5%-16%)和PASI90(18%-40% vs 0%)方面均优于赋形剂。
  • 所有差异在Tapinarof 1%每日一次组均具统计学显著性。
  • Tapinarof应答自第2周显现,第8周显著疗效维持至第16周。
  • 多数不良事件为轻或中度。

关键数值与推荐

  • PASI50:Tapinarof组71%-92%,赋形剂组10%-32%。
  • PASI75:Tapinarof组46%-65%,赋形剂组5%-16%。
  • PASI90:Tapinarof组18%-40%,赋形剂组0%。
  • 所有差异在Tapinarof 1%每日一次组均具统计学显著性。

临床怎么用

  • 对于斑块状银屑病成人患者,可考虑外用Tapinarof乳膏0.5%或1%每日一次或两次,疗效自第2周显现并维持至第16周。

局限性

  • 所报告的分析需在更大规模的前瞻性研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tapinarof cream is a topical therapeutic aryl hydrocarbon receptor modulating agent under investigation for treatment of psoriasis and atopic dermatitis. METHODS: In a phase 2b, double-blind, vehicle-controlled study, adults with plaque psoriasis were randomized to tapinarof cream 0.5% or 1% once or twice daily or vehicle once or twice daily for 12 weeks with 4-week follow-up. Efficacy outcomes included Physician Global Assessment (PGA) scores, change in PGA and total target lesion grading scores, and proportion of patients achieving ≥50%, ≥75%, and ≥90% reductions in the Psoriasis Area and Severity Index scores from baseline (PASI50, PASI75, and PASI90). RESULTS: At week 12, improvements were observed in all tapinarof groups vs vehicle in PGA response, change in PGA and total target lesion grading scores, PASI50 (71%-92% vs 10%-32%), PASI75 (46%-65% vs 5%-16%), and PASI90 (18%-40% vs 0%); all differences were statistically significant with tapinarof 1% once daily. Tapinarof responses were apparent from week 2, with significant efficacy at week 8 maintained through week 16. Most adverse events were mild or moderate. LIMITATIONS: The analyses reported require confirmation in larger prospective studies. CONCLUSIONS: Tapinarof may represent an important advance in the development of topical medicines for treatment of psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Stein Gold L, Bhatia N, Tallman AM, et al. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes. J Am Acad Dermatol. 2020. PMID: 32446832. doi:10.1016/j.jaad.2020.04.181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。